LEADERSHIP COUNCIL
Stony Brook University has established itself as one of America’s most dynamic public universities, a center of academic excellence and an essential part of the region’s economy. Now, transformed by a historic $150 million gift from Jim and Marilyn Simons and the Simons Foundation — among the top 10 gifts to public higher education in America — Stony Brook is poised to accelerate its trajectory of excellence.
U.S.News & World Report ranks Stony Brook among the top 100 universities in the nation, and the Times Higher Education World University Rankings places us among the top 1 percent of all the universities in the world. A member of the prestigious, invitation-only Association of American Universities, Stony Brook is one of the 61 leading research institutions in North America and the co-manager of Brookhaven National Laboratory. Nobel laureates, Guggenheim fellows and MacArthur grant winners teach on our campus, making it a magnet for outstanding students. The University offers more than 200 undergraduate and 140 graduate programs and has 24,100 students.
Stony Brook’s 1,040-acre campus on Long Island’s North Shore encompasses not only the main academic areas of the University, but also Stony Brook Medicine, which includes the five health sciences schools, Stony Brook University Hospital, Stony Brook Long Island Children’s Hospital, the Long Island State Veterans Home, and our major healthcare centers, programs and clinics. The University’s reach also extends to a Research and Development Park, four business incubators, Stony Brook Manhattan and our Southampton campus on Long Island’s East End.
www.stonybrook.edu | Facebook | Twitter: @stonybrooku
PLATINUM
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines.
www.medimmune.com | Twitter: @MedImmune | LinkedIn
Covington & Burling LLP offers one of the largest and most comprehensive life sciences-focused legal practices in the world. We represent biotech and pharmaceutical companies in the US, Europe, Asia and other markets. Covington’s multi-disciplinary and multi-jurisdictional approach combines our US and cross-border corporate transactional practice—including licensing and strategic collaborations, M&A, venture capital financings, IPOs and follow-on offerings, and royalty monetizations — with our regulatory and reimbursement expertise and our intellectual property/patent, litigation, product liability, government affairs, antitrust and trade capabilities. Our team features numerous alumni of the FDA, HHS and other key regulatory agencies in the US, Europe and Asia, as well as two former general counsels of pharmaceutical companies. We are the only firm recognized by Chambers as a “Band 1” firm for Life Sciences across their US, UK, Europe, China and Global surveys.
www.cov.com | Twitter: @CovingtonLLP
GOLD
Carter DeLuca Farrell & Schmidt, LLP, a leader in intellectual property law, provides cost effective services to a large cadre of national and international clients. Throughout the phases of product or brand development, we form a critical part of our client’s development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and follow on IP asset assimilation to help our clients achieve their business objectives.
www.cdfslaw.com
EisnerAmper LLP ranks as the 5th largest accounting and consulting firm in New York City. We provide audit, accounting, and tax services, as well as IPO, corporate finance, internal audit and risk management, litigation services, consulting, private business services, employee benefit plan audits, forensic accounting, and other professional advisory services to a broad range of clients, including pharmaceutical, biotechnology, and medical device companies.
We work with start-ups, high net worth individuals, family offices, closely held businesses, and Fortune 500 companies. EisnerAmper is PCAOB-registered and serves more than 200public companies and over 1,600 financial services entities and portfolio companies. As companies grow, we help them reach their goals every step of the way. Headquartered in New York City, we also have offices across the US and abroad to serve our in the US and worldwide.Contact Steve Kreit (steven.kreit@eisneramper.com) for more information.
www.eisneramper.com|LinkedIn |Facebook | Twitter:@EisnerAmper
External Innovation. Since Eli Lilly and Company was founded more than 135 years ago, our mission has remained unchanged: Create high-quality medicines that make life better. Healthcare challenges are complex and the unmet need is great; we know we can’t do it alone. We must be innovative in our science and in our approach to partnerships to bring medicines to the people who need them.
OUR APPROACH HAS THREE CRITICAL COMPONENTS:
COMMUNICATE: Hear your ideas, Share our interests, and Start the conversation
EXPLORE: Dive into the science, strategy, and commercial potential of every project
COLLABORATE: Integrate our collective strengths to shape the science to benefit patients
OUR GREATEST INTERESTS INCLUDE:
Oncology – Neuroscience – Diabetes- Immunology – Biotechnology Discovery Research- Emerging Markets- Drug Delivery and Devices- Cardiovascular
WE WOULD ALSO BE WILLING TO DISCUSS: Regional Innovation (Regional collaborations linking outstanding science with the expertise of Lilly scientists across a broad range of therapeutic areas); Chorus (A fully integrated Lilly R&D unit with the ability to be a strategic development partner for external programs). We are passionate about engaging in innovative partnerships in any of these areas.
www.lilly.com | www.advancinginnovation.lilly.com | Twitter: @LillyPad
At Kenyon & Kenyon, we partner with our clients to provide the full range of intellectual property services. We represent clients in a broad range of industries and technologies, including automotive, chemicals, computer hardware and software, financial services, food and beverage, interactive entertainment, life sciences, mechanical, media and sports, pharmaceuticals, retail, universities and research institutions, and venture capital. From our offices in New York, Washington and Silicon Valley, we serve clients in a cost-effective and efficient manner across the globe in such areas as federal court litigations; U.S. Patent Office post grant proceedings; trademark oppositions and cancellations; International Trade Commission proceedings; patent prosecution, counseling and portfolio management; trademark prosecution, counseling and portfolio management; trademark clearance; copyright counseling and licensing; trade secrets and unfair competition; brand and technology licensing and development agreements; and social media counseling. Our IP practice has received widespread recognition, having been named a Top IP Firm by such publications as Chambers USA,Legal 500, IAM 1000 – The World’s Leading Patent Practitioners,Managing Intellectual Property and World Trademark Review.
www.kenyon.com | Blogs | Twitter: @KenyonLaw
Merck has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide.
From Merck’s development of the first measles and mumps vaccines to breakthrough treatments for critical conditions such as Hepatitis C, high blood pressure, cancer and diabetes, we are an industry leader in bringing forth innovative new medicines.
Merck had sales of more than $42 billion in 2014 and we operate in more than 140 countries. Our research pipeline is stocked with promising drug candidates and our labs are pursuing some of the most innovative areas in biomedical research emerging today. Merck is fully committed to driving great science forward!
At Merck, we recognize that building partnerships is one of our most important jobs. In 2014, more than 58% of our human health sales were attributable to alliance partnerships and patents. Strong, lasting alliances are vital to us and to our mission to bring new hope to patients with serious diseases.
www.merck.com | Facebook | Twitter: @Merck
Target Health Inc., established in 1993, is a New York City-based full service eCRO with staff dedicated to all aspects of drug and device development including Regulatory Affairs and Strategic Planning, Chemistry Manufacturing and Controls, Clinical Research, Biostatistics, Data Management and Medical Writing.
Target Health has developed innovative web-based software tools that provide our clients with a transparent paperless environments and a significant productivity edge.
What differentiates Target Health?
– Extensive regulatory experience and represent over 35 companies at the FDA.
– Since 1993, Target Health has played a key role in bringing to market a total of 31 new drugs, biologics and device products. Of these approvals, there are now 23 products marketed worldwide that used Target e*CRF (EDC) for their pivotal trials.
– Target’s full suite of paperless clinical trial software including Target e*CRF® (EDC), Target e*CTR®(electronic medical record for clinical trials).Target e*ICF (informed consent), Target Document® (eTMF).
Contact: Warren M. Pearlson, Director Business Development |Target Health Inc. 261 Madison Avenue, New York, NY 10016 | 212-681-2100
wpearlson@targethealth.com
www.targethealth.com | blog: http://blog.targethealth.com/
SILVER
Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological conditions.
Acorda markets three FDA-approved therapies including: AMPYRA®(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with MS; ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda.
Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.
www.acorda.com | Twitter: @AcordaNews
Hoffmann & Baron, LLP is a full-service law firm specializing in all areas of intellectual property, both domestically and internationally. Intellectual property is among an organization’s most important assets. Hoffmann & Baron is an industry leader in patents, trademarks, copyright and trade secrets. We safeguard intellectual property assets through procurement, litigation, counseling, opinions and licensing.
Since 1984, Hoffmann & Baron, LLP has been working to protect ideas and to help transform those ideas into assets. What sets us apart is our personalized attention and ability to customize our services to fit the requirements of each client. We strive to provide timely and cost effective business-oriented counsel.
Hoffmann & Baron, LLP has offices in New York and New Jersey and serves clients around the globe in all scientific and engineering fields.
www.hbiplaw.com
The University at Buffalo’s New York State Center of Excellence in Bioinformatics & Life Sciences (CBLS) is your hub for life sciences innovation and technology-based economic development. As one of 10 New York State Centers of Excellence overseen by NYSTAR – Empire State Development’s Division of Science, Technology and Innovation – we leverage our resources to drive scientific discovery and facilitate collaboration among academia, industry and the public sector. By working with the CBLS, these researchers have access to world class facilities, faculty expertise, funding sources, workforce development talent and R&D assistance to continue to develop and patent new technologies to improve human health and expand our vibrant ecosystem. For more information on how to grow your business contact Kim Grant at kimgrant@buffalo.edu or 716-881-7572.
www.buffalo.edu/cbls | Facebook | Twitter: @UB_CBLS
Nixon Peabody’s nationwide Life Sciences Team matches your passion step for step, and covers the range of corporate, healthcare regulatory and other legal concerns you may encounter. With deep experience in the Life Sciences industry, we help emerging companies with business formation, governance matters, branding and intellectual property protection, licensing, joint ventures, stock plans and compensation, immigration, finance and strategic planning, and global expansion. We facilitate introductions to funding sources including angel, venture, and private equity capital in addition to structuring and handling your financings. We assist clients in navigating the complexities of federal and state laws including securities law compliance, and other regulatory matters. Recently recognized by U.S. News-Best Lawyers as 2016 Law Firm of the Year in Health Care Law, Nixon Peabody has the experience, insight, and resources you require to help you as you encounter legal and business decisions that impact your future success.
www.nixonpeabody.com | LinkedIn | Twitter:@NixonPeabodyLLP
![PMI-Logo-Ai-[Converted]](http://2015.lifesciencessummit.org/wp-content/uploads/2014/05/PMI-Logo-Ai-Converted.gif){kind=logo}
Preclinical Medevice Innovations (PMI) is a leader in preclinical medical device contract research with over 25 years of experience in experimental surgery. With four surgical suites and imaging equipment including a Cath lab, c-arms, ultrasound, endo and lap towers, PMI is fully equipped to handle all of your study needs from research and development to non-GLP and GLP. We take a collaborative approach with our clients understanding the complexities of research and the unique needs of individual companies. Our longevity coupled with our expertise will help you get your device to the market more effectively and efficiently than any other preclinical medical device CRO.
www.pmipreclinical.com
Celebrating its 42nd year, Garden City-based Scully, Scott, Murphy & Presser, P.C. is one of Long Island’s largest and most prominent law firms exclusively dedicated to Intellectual Property. Comprised of highly skilled attorneys with highly technical backgrounds, SSMP confidently sits at the crossroads of cutting edge science, technology and law where it offers detailed, insightful opinions and secures, protects and enforces intellectual property for its clients. Intellectual Property Today has consistently ranked SSMP among the top 10% of patent firms in the United States, ranked #26 nationally, #3 in the New York Metro area and remains #1 on Long Island.
We continue to grow in the areas of biotechnology, chemistry, electronics, electrical engineering, computer science, internet, business methods, mechanical arts, nanotechnology, pharmaceuticals and material science. For more information, please visit our website or call 516-742-4343.
www.ssmp.com
SUPPORTERS
National Institutes of Health
National Institute of Neurological Disorders and Stroke
National Heart, Lung and Blood Institute
Empire State Development’s Division of Science, Technology and Innovation (NYSTAR) mission is to accelerate the growth of New York State’s high-tech economy. NYSTAR’s programs are designed to enable new and existing businesses to become more competitive through the use of innovative technologies, and emphasize the importance of working with industry to leverage the state’s technology strengths to produce new products and, therein, new and expanded jobs in the state.
Through funded programs which support world-class technology research at colleges and universities, NYSTAR works to promote a robust network of industry-university partnerships throughout the state. Its support of Regional Technology Development Centers provides direct technology assistance to small and medium size manufacturers and other businesses.
NYSTAR’s responsibilities include the administration and oversight of the following state programs:Centers of Excellence, Centers for Advanced Technology, Regional Technology Development Centers, and High Performance Computing. NYSTAR and its partners are proud to be contributing to the growth of the Innovation Economy in New York State.
esd.ny.gov/nystar/